SG10201804034QA - Methods for treating hypotension - Google Patents

Methods for treating hypotension

Info

Publication number
SG10201804034QA
SG10201804034QA SG10201804034QA SG10201804034QA SG10201804034QA SG 10201804034Q A SG10201804034Q A SG 10201804034QA SG 10201804034Q A SG10201804034Q A SG 10201804034QA SG 10201804034Q A SG10201804034Q A SG 10201804034QA SG 10201804034Q A SG10201804034Q A SG 10201804034QA
Authority
SG
Singapore
Prior art keywords
methods
hypotension
treating hypotension
treating
angiotensin
Prior art date
Application number
SG10201804034QA
Inventor
George Tidmarsh
Lakhmir Chawla
Original Assignee
La Jolla Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharma Co filed Critical La Jolla Pharma Co
Publication of SG10201804034QA publication Critical patent/SG10201804034QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

METHODS FOR TREATING HYPOTENSION The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant: hypotension. Figure: None
SG10201804034QA 2014-07-08 2015-07-08 Methods for treating hypotension SG10201804034QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462022054P 2014-07-08 2014-07-08

Publications (1)

Publication Number Publication Date
SG10201804034QA true SG10201804034QA (en) 2018-07-30

Family

ID=55064810

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201610897VA SG11201610897VA (en) 2014-07-08 2015-07-08 Methods for treating hypotension
SG10201804034QA SG10201804034QA (en) 2014-07-08 2015-07-08 Methods for treating hypotension

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201610897VA SG11201610897VA (en) 2014-07-08 2015-07-08 Methods for treating hypotension

Country Status (14)

Country Link
US (3) US20160074465A1 (en)
EP (2) EP3007722A4 (en)
JP (2) JP2017519799A (en)
KR (1) KR20170026486A (en)
CN (1) CN106794224A (en)
AU (2) AU2015287955A1 (en)
BR (1) BR112017000303A2 (en)
CA (1) CA2954016A1 (en)
EA (2) EA036514B1 (en)
IL (1) IL249936A0 (en)
MX (1) MX2017000306A (en)
SG (2) SG11201610897VA (en)
TW (3) TWI688385B (en)
WO (1) WO2016007589A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
BR112016013961A2 (en) 2013-12-18 2017-10-10 The George Washington Univ A Congressional Chartered Not For Profit Corporation angiotensin ii alone or in combination for the treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2019501201A (en) 2016-01-07 2019-01-17 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ Method of administering angiotensin II
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
US20190183962A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
US10653646B2 (en) * 2018-03-23 2020-05-19 Nevakar Inc. Epinephrine compositions and containers
KR102258546B1 (en) 2018-10-26 2021-06-01 양성심 Health functional food composition comprising organic cale as main component

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
DE602006021600D1 (en) * 2005-09-29 2011-06-09 Fibrogen Inc METHOD FOR REDUCING BLOOD PRESSURE
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) * 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
BR112016013961A2 (en) * 2013-12-18 2017-10-10 The George Washington Univ A Congressional Chartered Not For Profit Corporation angiotensin ii alone or in combination for the treatment of hypotension

Also Published As

Publication number Publication date
KR20170026486A (en) 2017-03-08
AU2015287955A1 (en) 2017-02-02
TWI688385B (en) 2020-03-21
US20160074465A1 (en) 2016-03-17
EP3007722A1 (en) 2016-04-20
AU2021201669A1 (en) 2021-04-08
EA201692534A1 (en) 2017-06-30
EA036514B1 (en) 2020-11-18
MX2017000306A (en) 2017-07-10
TW201625231A (en) 2016-07-16
EP3381465A1 (en) 2018-10-03
CN106794224A (en) 2017-05-31
TW202038927A (en) 2020-11-01
EA202091873A3 (en) 2021-01-29
WO2016007589A1 (en) 2016-01-14
TW202214219A (en) 2022-04-16
US20200237853A1 (en) 2020-07-30
TWI754225B (en) 2022-02-01
CA2954016A1 (en) 2016-01-14
EP3007722A4 (en) 2016-05-25
BR112017000303A2 (en) 2017-11-07
JP2017519799A (en) 2017-07-20
US20180311306A1 (en) 2018-11-01
JP2020143139A (en) 2020-09-10
SG11201610897VA (en) 2017-01-27
EA202091873A2 (en) 2020-11-30
IL249936A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2017010150A (en) Recombinant probiotic bacteria.
SG10201804034QA (en) Methods for treating hypotension
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2017011834A (en) Peptidomimetic macrocycles and uses thereof.
MX2017003797A (en) Peptidomimetic macrocycles and uses thereof.
HRP20190194T1 (en) 17a,21-diesters of cortexolone for use in the treatment of tumors
MX2017006015A (en) Apilimod for use in the treatment of renal cancer.
MX2017000142A (en) Mesenchymal stromal cells for treating sepsis.
EA201692284A1 (en) NIACINAMIDE FOR STIMULATING THE PRODUCTION OF ANTIMICROBIAL PEPTIDES
NZ722600A (en) Methods of treating mild brain injury
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
MX2016009655A (en) Novel methods for treating cancer.
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
PH12016502150A1 (en) Method for treating renal cell carcimona
JO3541B1 (en) Medical treatments based on anamorelin
MX2019004804A (en) Treatment of prurigo nodularis.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX2019003755A (en) Dosing regimen of avelumab for the treatment of cancer.
MX2018011379A (en) Treatment of uremic pruritus.
EA201590615A1 (en) STIMULATING LACTATION COMPOSITIONS BASED ON PHOSPHATIDIDILSERIN
EA201691036A1 (en) NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA
EA201690914A1 (en) NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA
MX362111B (en) A method of improving liver function.
MA40574A (en) Treatment of fibrotic diseases